Clinical Characteristics and Medical Utilization of Smokers with Preserved Ratio Impaired Spirometry.
emergency department
hospitalization
lung function
restrictive lung disease
wheezing
Journal
International journal of chronic obstructive pulmonary disease
ISSN: 1178-2005
Titre abrégé: Int J Chron Obstruct Pulmon Dis
Pays: New Zealand
ID NLM: 101273481
Informations de publication
Date de publication:
2023
2023
Historique:
received:
02
08
2023
accepted:
01
10
2023
medline:
13
10
2023
pubmed:
12
10
2023
entrez:
12
10
2023
Statut:
epublish
Résumé
To investigate the clinical characteristics and medical utilization of smokers with preserved ratio impaired spirometry (PRISm). We used data from the Korean National Health and Nutrition Examination Survey between 2007 and 2012, linked to the Health Insurance Review and Assessment Service. Clinical characteristics and medical utilization, including inpatient admission, emergency department visit, prescribed medication, and medical cost, were retrospectively compared among three groups: normal spirometry, PRISm, and chronic obstructive pulmonary disease (COPD). A total of 7115 smokers were included (4743 normal spirometry, 689 PRISm, and 1683 COPD subjects). The mean age was the highest in the COPD group, followed by the PRISm and normal groups, and the proportion of women was the highest in the PRISm group. The tobacco exposure, socioeconomic status (SES), and schooling level of the PRISm group were at levels between those of the normal and COPD groups. However, the PRISm group had the highest proportion of current smokers, highest body mass index (BMI), and lowest mean FEV Medical utilization was comparable between the PRISm and COPD groups. Smokers with PRISm who were older, women, or heavy smokers with low BMI, low SES and schooling level, wheezing, or low FEV
Identifiants
pubmed: 37822330
doi: 10.2147/COPD.S425934
pii: 425934
pmc: PMC10563768
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2187-2194Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023 Shin et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Int J Epidemiol. 2014 Feb;43(1):69-77
pubmed: 24585853
Am J Respir Crit Care Med. 2018 Dec 1;198(11):1397-1405
pubmed: 29874098
Am J Respir Crit Care Med. 2022 Sep 1;206(5):563-572
pubmed: 35549659
Lancet Respir Med. 2022 Feb;10(2):149-157
pubmed: 34739861
Eur Respir J. 2022 Jul 13;60(1):
pubmed: 34949706
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2017-21
pubmed: 18250302
Int J Tuberc Lung Dis. 2017 Sep 1;21(9):1062-1068
pubmed: 28826457
Medicina (Kaunas). 2020 Dec 23;57(1):
pubmed: 33374629
Eur Respir J. 2005 Jun;25(6):1011-7
pubmed: 15929955
JAMA. 2021 Dec 14;326(22):2287-2298
pubmed: 34905031
Am J Respir Crit Care Med. 2000 Oct;162(4 Pt 1):1239-45
pubmed: 11029324
Eur Respir J. 2023 Apr 1;61(4):
pubmed: 36858443
Am J Physiol Lung Cell Mol Physiol. 2004 Sep;287(3):L497-502
pubmed: 15145787
Am J Respir Crit Care Med. 2021 Oct 15;204(8):910-920
pubmed: 34233141
J Asthma. 2011 Oct;48(8):811-7
pubmed: 21942353
Respiration. 2022;101(1):25-33
pubmed: 34320510
Tuberc Respir Dis (Seoul). 2021 Oct;84(4):274-281
pubmed: 33940672
Eur Respir J. 2017 May 25;49(5):
pubmed: 28546266
Respir Res. 2014 Aug 06;15:89
pubmed: 25096860
Respir Med. 2016 Nov;120:116-123
pubmed: 27817808
Eur Respir J. 2004 Jun;23(6):932-46
pubmed: 15219010
Respir Med. 2020 Jan;161:105820
pubmed: 31759270
Chest. 2011 Apr;139(4):878-886
pubmed: 20724741
Thorax. 2010 Jun;65(6):499-504
pubmed: 20522846
Int J Chron Obstruct Pulmon Dis. 2021 Sep 23;16:2665-2675
pubmed: 34588775
Am J Respir Crit Care Med. 2016 Apr 1;193(7):727-35
pubmed: 26540012
Int J Chron Obstruct Pulmon Dis. 2018 Mar 14;13:903-915
pubmed: 29559774